TY - JOUR
T1 - Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-GD3 ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts
AU - Lee, Fook Thean
AU - Rigopoulos, Angela
AU - Hall, Cathrine
AU - Clarke, Kerrie
AU - Cody, Stephen H.
AU - Smyth, Fiona E.
AU - Liu, Zhanqi
AU - Brechbiel, Martin W.
AU - Hanai, Nobuo
AU - Nice, Edouard C.
AU - Catimel, Bruno
AU - Burgess, Antony W.
AU - Welt, Sydney
AU - Ritter, Gerd
AU - Old, Lloyd J.
AU - Scott, Andrew M.
PY - 2001/6/1
Y1 - 2001/6/1
N2 - The chimeric monoclonal antibody KM871, directed against the GD3 antigen, is under evaluation for its potential to target melanoma. To facilitate the in vivo evaluation of biodistribution properties and measurement of pharmacokinetics, KM871 was radiolabeled with 125I via tyrosine residues and with 111In via the bifunctional metal ion chelator C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid (CHX-A″-DTPA) to lysine residues. Using antigen-positive SK-MEL-28 melanoma cells, immunoreactivities of 42 and 40% cell binding were obtained, respectively, for the two radioconjugates. Binding was enhanced in the presence of added unlabeled antibody. A humanized A33 antibody was similarly labeled with the two isotopes and used as a control. To determine and compare in vivo biodistribution characteristics of KM871 radiolabeled with 111In or 125I, mixtures of the radioconjugates were injected i.v. into BALB/c nude mice bearing GD3-positive-SK-MEL-28 melanoma xenografts. Gamma camera images were acquired; groups of five mice were sacrificed at various time intervals, and tumors, blood, and tissues were analyzed, 111In-labeled CHX-A″-DTPA-KM871 showed a maximum tumor uptake of 41.9 ± 7.0% injected dose/g at 72 h with prolonged retention over a 15-day period. The tumor:blood ratio was 3:1 by 72 h, and higher ratios were observed at later time points. No abnormal accumulation of 111In-labeled conjugate was found in normal tissues. In contrast, there was little accumulation of 125I-labeled KM871 in the same tumors. The specificity of antibody localization was confirmed by the low tumor uptake values for radiolabeled control antibody. Gamma camera imaging demonstrated excellent uptake of 111In-labeled CHX-A″-DTPA-KM871 in the xenografts. Chromatographic analyses of xenograft cytosolic extracts demonstrated tumor internalization and catabolism of radiolabeled KM871 with the formation of small molecular weight metabolites. Laser scanning confocal microscopy demonstrated that the majority of intracellular KM871 is localized to lysosomes. Despite the catabolism of the radioconjugate, a dose-dependent increase in KM871 tumor localization was shown through immunohistochemical examination of xenograft biopsies. This study demonstrates for the first time the in vivo localization of a radiolabeled anti-GD3 monoclonal antibody to GD3expressing xenografts using gamma camera scanning techniques and tumor cell internalization of KM871 tagged with a green fluorescent dye, Alexa Fluor 488, through confocal microscopy. KM871 has potential for targeting tumors in patients with melanoma.
AB - The chimeric monoclonal antibody KM871, directed against the GD3 antigen, is under evaluation for its potential to target melanoma. To facilitate the in vivo evaluation of biodistribution properties and measurement of pharmacokinetics, KM871 was radiolabeled with 125I via tyrosine residues and with 111In via the bifunctional metal ion chelator C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid (CHX-A″-DTPA) to lysine residues. Using antigen-positive SK-MEL-28 melanoma cells, immunoreactivities of 42 and 40% cell binding were obtained, respectively, for the two radioconjugates. Binding was enhanced in the presence of added unlabeled antibody. A humanized A33 antibody was similarly labeled with the two isotopes and used as a control. To determine and compare in vivo biodistribution characteristics of KM871 radiolabeled with 111In or 125I, mixtures of the radioconjugates were injected i.v. into BALB/c nude mice bearing GD3-positive-SK-MEL-28 melanoma xenografts. Gamma camera images were acquired; groups of five mice were sacrificed at various time intervals, and tumors, blood, and tissues were analyzed, 111In-labeled CHX-A″-DTPA-KM871 showed a maximum tumor uptake of 41.9 ± 7.0% injected dose/g at 72 h with prolonged retention over a 15-day period. The tumor:blood ratio was 3:1 by 72 h, and higher ratios were observed at later time points. No abnormal accumulation of 111In-labeled conjugate was found in normal tissues. In contrast, there was little accumulation of 125I-labeled KM871 in the same tumors. The specificity of antibody localization was confirmed by the low tumor uptake values for radiolabeled control antibody. Gamma camera imaging demonstrated excellent uptake of 111In-labeled CHX-A″-DTPA-KM871 in the xenografts. Chromatographic analyses of xenograft cytosolic extracts demonstrated tumor internalization and catabolism of radiolabeled KM871 with the formation of small molecular weight metabolites. Laser scanning confocal microscopy demonstrated that the majority of intracellular KM871 is localized to lysosomes. Despite the catabolism of the radioconjugate, a dose-dependent increase in KM871 tumor localization was shown through immunohistochemical examination of xenograft biopsies. This study demonstrates for the first time the in vivo localization of a radiolabeled anti-GD3 monoclonal antibody to GD3expressing xenografts using gamma camera scanning techniques and tumor cell internalization of KM871 tagged with a green fluorescent dye, Alexa Fluor 488, through confocal microscopy. KM871 has potential for targeting tumors in patients with melanoma.
UR - http://www.scopus.com/inward/record.url?scp=0035361342&partnerID=8YFLogxK
M3 - Article
C2 - 11389078
AN - SCOPUS:0035361342
SN - 0008-5472
VL - 61
SP - 4474
EP - 4482
JO - Cancer Research
JF - Cancer Research
IS - 11
ER -